公司财务表现 - 2025年第三季度总产品收入为230万美元，与2024年同期相比基本持平 [1] 公司业务与定位 - 公司是一家专注于妇科疾病诊断和管理的女性健康公司，业务基础为人工智能增强的生物分析技术 [1] - 公司致力于提供领先的非侵入性妇科疾病诊断和疾病管理工具 [1] 报告时间范围 - 本次公布的业绩涵盖截至2025年9月30日的三个月和九个月期间 [1]

$2.95 Million PIPE $112 thousand warrant exercise AUSTIN, TX / ACCESS Newswire / September 18, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostics and disease management tools, today announced that it has received equity capital totaling $3.06 million from existing and new investors. The company has entered into a securities purchase agreement dated September 18, 2025, p ...